Product Images Pemetrexed

This text is providing information on survival probability for two different drugs used for cancer treatment (Pemetrexed + Cisplatin and Gemcitabine + Cisplatin) and the corresponding survival time in months. It also gives the number of patients at risk for a certain period.*

This is a comparative analysis of survival probability of patients who received Pemetrexed+Cisplatin (PC) chemotherapy treatment and those with Gemcitabine+Cisplatin (GC) chemotherapy. The observation spanned for a period of 27 months. The measurement was done by taking into consideration the number of patients that were still alive at a six-month interval over the period of study. The data is presented on a chart, which shows the number of patients at risk for each treatment for a given survival time in months.*

The given text represents a survival probability chart for two chemotherapy treatments namely Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC). This chart shows the probability of survival for each treatment over a period of 18 months with survival time (months) on x-axis, probability of survival on y-axis and the number of patients at risk for each treatment. Therefore, it can be useful for evaluating the effectiveness of both treatments in increasing the survival probability of patients undergoing chemotherapy.*

This is a survival analysis for a clinical trial comparing pemetrexed and placebo treatments. The data shows the number of patients at risk and survival probabilities at various time points, measured in months. The survival curves for the two treatments differ, with pemetrexed having higher survival rates than placebo. The data does not provide further context for the trial or the medical condition being studied.*

This appears to be a chart showing the Survival Probability of patients receiving Pemetrexed versus a Placebo. The chart also includes the number of patients at risk for each treatment and the Survival Time in months. However, the chart is not entirely readable and some of the numbers are unclear.*

This appears to be a table displaying patient data for a chemotherapy treatment involving Pemetrexed and Cisplatin. The table contains columns indicating the number of patients at risk, the treatment combination, and survival time in months. The rows list numerical values for each category, possibly including statistics such as percentages or frequencies.*

This text describes the composition, storage, and cautionary instructions for a medication called Pemetrexed Disodium in powder form. Each vial contains 100mg of the medication and 106mg of mannitol. It also mentions the addition of Hydrochloric acid and/or Pemetrexed sodium hydroxide to adjust pH. It stresses that the medication should be stored within the range of 15°C to 30°C and warns that it is a Cytotoxic Agent, hence should be used for intravenous purposes only. Any additional instructions for reconstituting and infusing the medication can be found in the accompanying literature.*

This is a description of a pharmaceutical product containing pemetrexed disodium in a vial. The vial contains 100mg pemetrexed and 106mg of mannitol. The vial has a 2D barcode encoded with all data presented in a human-readable format for online printing of LOT, EXP, Serial Number, and GTIN. It has an unvarnished area reserved for the barcode. The powder needs to be stored at 25°C with excursions permitted to 15°C to 30°C. To reconstitute, 4.2 mL of 0.8% Sodium Chloride injection is added to make a solution containing 25 mg/mL of pemetrexed. The reconstituted solution must be further diluted before use. It should be administered within 24 hours afer initial reconstitution. The pharmaceutical product is not available for oral intake and caution against cytotoxic agent. The unused portion in the single-dose vial should be discarded. The product is manufactured for Ingenus Pharmaceuticals, LLC in Orlando, FL and made in Chira.*

Each vial of NDC 50742-341-01 contains 500 mg of pemetrexed disodium equivalent to 500 mg of mannitol. The pH may have been adjusted using hydrochloric acid and/or sodium hydroxide for injection. The powder should be stored at 25°C (77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). This product is a cytotoxic agent meant for intravenous use only. Storage instructions for reconstituted and infusion solutions can be found in the accompanying literature. Made in China.*

This is a description of a medicine called Pemetrexed for Injection, USP, which is a cytotoxic agent meant for intravenous use only. It comes as a single-dose vial, and any unused portions should be discarded. To reconstitute the medicine, 20 mL of 0.9% Sodium Chloride Injection is added to make a solution containing 25 g/ pemetrexed, which must be further diluted before use. The reconstituted and infusion solutions should be stored refrigerated at 2°C to 8°C; the powder should be stored at 25°C, with excursions permitted to 15°C to 30°C. The accompanying literature contains information on the dose, and the manufacturer is Ingens Pharmaceuticals.*